Jordan Davisson Cook

Jordan’s recent cases include representing:

• Amgen – Obtained complete summary judgment in a securities class action alleging false and misleading statements relating to Phase III trial results and a New Drug Application (N.D. Cal.)
• Desktop Metal – Defeated motion to expedite breach of fiduciary duty claims against Desktop Metal and certain of its officers and directors in the Delaware Court of Chancery in connection with a shareholder rights plan (Del. Ch.)
• Masimo – Won civil contempt order and sanctions against activist stockholder in connection with proxy contest for control of healthcare-technology company’s board (C.D. Cal.)
• Kohl’s – Won dismissal of securities class action involving retailer’s management of supply chain matters and revenue reporting (E.D. Wis.)
• GoodRx – Won dismissal of a securities class action challenging statements related to GoodRx’s disclosures surrounding its relationship with large grocery chain (C.D. Cal.)
• Puma Biotechnology: At trial, defeated more than 95 percent of plaintiffs’ claimed damages in rare Section 10(b) securities class action to go to jury verdict, named by the Daily Journal as one of the Top Verdicts of 2019 (C.D. Cal.)
• GoodRx – Won final dismissal of securities class action challenging company’s IPO disclosures following major competitor’s entry into prescription-drug pricing market (C.D. Cal.)
• OSI Systems – Won dismissal of securities fraud claims against electronic systems developer and senior executives based on claims prompted by short seller Muddy Waters (C.D. Cal.)
• Alteryx – Won final first-round dismissal of securities class action against technology company following withdrawal of guidance in the early days of the pandemic (C.D. Cal.)
• Desktop Metal, Inc. – Won dismissal of securities fraud claims against 3D printing company based on whistleblower investigation (Del. Ch.)
• Investment Banks – Achieved walk-away settlement and dismissal of underwriters in Section 11 litigation arising from IPO of ChemBio (E.D.N.Y.)
• Prometheus Biosciences in its US$11 billion acquisition by Merck (D. Del., S.D.N.Y.)
• Cerner Corp. in US$28.3 billion acquisition by Oracle (E.D.N.Y.), named among the Deal Awards Most Outstanding Deal of the Year in 2022